Home
    Disclaimer
    Cyclizine molecular structure

    Cyclizine Stats & Data

    Psychoactive Class Depressant

    Pharmacology

    DrugBank
    Half-life 20 hours State Solid

    Description

    A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)

    Mechanism of Action

    Vomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of cyclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since cyclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked.

    Pharmacodynamics

    Cyclizine is a piperazine-derivative antihistamine used as an antivertigo/antiemetic agent. Cyclizine is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which cyclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects.

    Metabolism

    Cyclizine is metabolised to its N-demethylated derivative, norcyclizine, which has little antihistaminic (H1) activity compared to Cyclizine.

    Indication

    For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo (dizziness caused by other medical problems).

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 3d Half tolerance 8d Baseline ~14d

    Experience Report Analysis

    Erowid
    12 Reports
    1993–2013 Date Range
    4 With Age Data
    13 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 12 experience reports (12 Erowid)

    12 Reports
    13 Effects Detected
    5 Positive
    3 Adverse
    5 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 5

    Anxiety Suppression 75.0% 70%
    Color Enhancement 41.7% 70%
    Stimulation 33.3% 70%
    Sedation 25.0% 70%
    Music Enhancement 25.0% 70%

    Adverse Effects 3

    Nausea 50.0% 70%
    Increased Heart Rate 41.7% 70%
    Confusion 25.0% 70%

    Real-World Dose Distribution

    62K Doses

    From 13 individual dose entries

    Oral (n=6)

    Median: 287.5mg 25th: 56.25mg 75th: 575.0mg 90th: 700.0mg

    Form / Preparation

    Most common forms and preparations reported

    Redose Patterns

    Redosing behavior across 10 reports

    10.0% Redosed
    1.1 Avg Doses
    61m Median Interval
    ← Back to Cyclizine